Only COVID-19 patients who have pre-existing conditions that require the usage of anticoagulant and antiplatelet drugs must continue its intake.
Only COVID-19 patients who have pre-existing conditions that require the usage of anticoagulant and antiplatelet drugs must continue its intake. The incidence of venous thromboembolism (VTE) in COVID-19 patients is not well established. Reports have ranged between 1.1% in non-ICU hospital wards to 69% in ICU patients screened with lower extremity ultrasound. Medical patients with more severe disease, especially if they have additional risk factors like obesity, cancer, history of VTE, comorbid conditions, ICU care, and coagulation, have a higher risk of VTE than those with mild or asymptomatic disease. VTE rates in outpatients are unreported. Patients who have thrombotic and cardiac disorders receive anticoagulant or antiplatelet therapies for underlying conditions. They must continue those medications if they receive a diagnosis of COVID-19.
Therefore, COVID-19 patients who experience an incident thromboembolic events should take antiplatelet therapy after discharge, with the doctor's consultation. The quantity of those medicines depends on patients' conditions
The COVID-19 pandemic has given rise to a lot of potentially dangerous misinformation. For reliable advice on COVID-19 including symptoms, prevention and available treatment, please refer to the World Health Organisation or your national healthcare authority.
Copied!